BioSpace - Aradigm Corporation News, Search Jobs, Events

Industry

Segment

Collaborations

Novo Nordisk A/S Commercial agreement to develop AERx technology for the delivery of insulin, insulin analogues and other glucose-lowering agents for diabetes management.

GlaxoSmithKline Agreement to develop AERx technology for the delivery of morphine and fentanyl for pain management.

University Of Torino Aradigm has additional undisclosed partnerships with both platforms looking at developmental and marketed products.

GlaxoSmithKline (North Carolina)

Grifols Signs Deal to License Aradigm Corporation (ARDM)'s Pulmaquin for Up to $90.7 Million 5/21/2013 7:01:13 AM More...

Aradigm Corporation (ARDM) Announces First Quarter 2013 Financial Results 5/14/2013 8:16:18 AM More...

Aradigm Corporation (ARDM) Announces Fourth Quarter 2012 and Full Year Financial Results 3/26/2013 6:33:34 AM More...

Aradigm Corporation (ARDM) to Present at Biotech Showcase 2013 on January 9 1/3/2013 6:26:04 AM More...

Aradigm Corporation (ARDM) Announces Third Quarter 2012 Financial Results 11/8/2012 9:59:08 AM More...

Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm Corporation (ARDM)'s Inhaled Liposomal Ciprofloxacin 10/16/2012 10:07:55 AM More...

UK Scientists Report Successful Testing of Aradigm Corporation (ARDM)'s Inhaled Liposomal Ciprofloxacin in Q Fever 9/20/2012 9:28:39 AM More...

New U.S. Composition of Matter Patent for Aradigm Corporation (ARDM)'s Pulmaquin™ and Lipoquin™ Provides Protection Until 2031 9/18/2012 8:41:07 AM More...

Aradigm Corporation (ARDM) Patent Protection for Smoking Cessation is Extended With Issuance of a Method of Treatment Patent 9/5/2012 10:33:34 AM More...

Aradigm Corporation (ARDM) to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis 8/30/2012 10:05:49 AM More...

...